Neutrophil-lymphocyte ratio, Pan-Immune-Inflammation Value and platelet-lymphocyte ratio as prognostic markers of recurrence-free survival in locally advanced cervical cancer, at the Hospital Miguel Hidalgo in the City of Aguascalientes, Mexico

Abstract

Abstract: Introduction: Cervical cancer (CaCU) continues to be an important cause of mortality in our country and in Aguascalientes. Objective: To evaluate the prognostic impact of neutrophil-lymphocyte ratio (RNL), platelet-lymphocyte ratio (RPL), and Pan-Immune-Inflammation Value (PIV) on recurrence-free survival (RFS) in patients with locally advanced cervical cancer. Material and methods: Observational, retrospective, longitudinal study in which 65 patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy were included. The cut-off points of the RNL, RPL and PIV were determined using ROC curves, the Kaplan-Meier method was used to determine the RFS, Log-Rank test and univariate and multivariate analysis was performed. Results: The median RFS in patients with an RNL ≥2.4 was 55 versus 8 months with an RNL <2.4 (p=0.0089). For RPL ≥147 it was 65 versus 8 months with RPL<147 (p=0.001). For PIV ≥310, the median RFS was 55 versus 6 months in those who had a PIV <310, (p=0.008). In the univariate analysis, the relative risk (RR) of the ≥2.4 RNL was 2.104 (95% CI 1.1-4.23, p= 0.025); for the RPL it was 1.008 (95% CI 1.001-1.015, p=0.041) and for the PIV was 1.006 (95% CI 1.001-1.01, p=0.016), in the multivariate analysis, only the RNL (p= 0.025), and the PIV (p=0.03) maintain significance. Conclusion: An RNL ≥2.4 and a > 310 PIV are significantly associated with an increased risk of recurrence in patients with locally advanced cervical cancer; although prospective studies are required to confirm these findings.

Fecha de recepción: 22/07/2023

Aceptación de originales: 05/08/2024